References
Yubero-Lahoz S, Pardo R, Farré M, O’Mahony B, Torrens M, Mustata C, Pérez-Mañá C, Carbó ML, de la Torre R (2011) Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet 50:319–329
Henry JA, Hill IR (1998) Fatal interaction between ritonavir and MDMA. Lancet 352:1751–1752
Harrington RD, Woodward JA, Hooton TM, Horn JR (1999) Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 159:2221–2224
de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, Camí J (2000) Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. Br J Clin Pharmacol 49:104–109
O’Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, de la Torre R (2008) The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 28:523–529
Acknowledgments
This work was supported by grants from DIUE de la Generalitat de Catalunya (2009 SGR 718), ISCIII-FEDER-FIS-RTA RD06/0001/1009 and ISCIII-FIS-CAIBER CAI08/01/0024.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papaseit, E., Vázquez, A., Pérez-Mañá, C. et al. Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). Intensive Care Med 38, 1239–1240 (2012). https://doi.org/10.1007/s00134-012-2537-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-012-2537-9